In fact, A2AR modulation of normal or hyperdopaminergic conditions is relevant to psychopharmacology [117, 118], whereas the A2AR control of the hypodopaminergic condition is directly relevant to Parkinson’s disease (PD) therapy [38, 180]. The gene discussed is ADORA2A; the disease is Parkinson disease.